Cargando…
Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
BACKGROUND: The addition of Rituximab (R) to standard chemotherapy (C) has been reported to improve the end of treatment outcome in patients affected by CD-20 positive malignant lymphomas (CD20+ ML). Nevertheless, given the profound and prolonged immunosuppression produced by R there are concerns th...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094236/ https://www.ncbi.nlm.nih.gov/pubmed/21481281 http://dx.doi.org/10.1186/1741-7015-9-36 |